Controlled Delivery of Corticosteroids Using Tunable Tough Adhesives. Issue 3 (9th November 2022)

• Record Type: Journal Article
• Authors: Koh, Esther; Freedman, Benjamin R; Ramazani, Farshad; Gross, Johannes; Graham, Adam; Kuttler, Andreas; Weber, Eckhard; Mooney, David J
• Is Part Of: Advanced healthcare materials. Volume 12:Issue 3(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-11-09
• Subjects: biomaterials -- corticosteroid -- drug delivery -- tough hydrogels; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/adhm.202201000
• Languages: English
• ISSNs: 2192-2640

Abstract

Abstract: Hydrogel‐based drug delivery systems typically aim to release drugs locally to tissue in an extended manner. Tissue adhesive alginate‐polyacrylamide tough hydrogels are recently demonstrated to serve as an extended‐release system for the corticosteroid triamcinolone acetonide. Here, the stimuli‐responsive controlled release of triamcinolone acetonide from the alginate‐polyacrylamide tough hydrogel drug delivery systems (TADDS) and evolving new approaches to combine alginate‐polyacrylamide tough hydrogel with drug‐loaded nano and microparticles, generating composite TADDS is described. Stimulation with ultrasound pulses or temperature changes is demonstrated to control the release of triamcinolone acetonide from the TADDS. The incorporation of laponite nanoparticles or PLGA microparticles into the tough hydrogel is shown to further enhance the versatility to control and modulate the release of triamcinolone acetonide. A first technical exploration of a TADDS shelf‐life concept is performed using lyophilization, where lyophilized TADDS are physically stable and the bioactive integrity of released triamcinolone acetonide is demonstrated. Given the tunability of properties, the TADDS are a suggested technology platform for controlled drug delivery. Abstract : This study reports alginate‐polyacrylamide tough hydrogel drug delivery systems (TADDS) for the stimuli‐responsive release of triamcinolone acetonide. Stimulation with ultrasound pulses or temperature changes control the release of triamcinolone acetonide from the TADDS, and the incorporation of laponite nanoparticles or PLGA microparticles further extend release. Given its tunability, the TADDS are a technology platform for controlled drug delivery.